GEN-MKT-18-7897-A
Mar 17, 2017 | Biopharma, Blogs | 0 comments
There is a lot of talk going around in the lab, and it has to do with the newly released Fast Glycan Labeling and Analysis technology. Where once research analysts needed to set aside days to perform glycan analysis, now takes an hour or so. Glycans are immediately identified by the software – so no need for data interpretation. That’s up to 5x faster than HILIC.
Short and simple 60-minute sample prep, followed by a 5-minute high-resolution separation provide immediate glycan identification and quantitation. Since glycan identification is automated, the Fast Glycan technology also eliminates the need for manual database searches while removing the potential for human error from the process.
Bioprocess International recognized our Fast Glycan technology and awarded it the 2016 Best Technology Application – Analytical Award.
Based on magnetic bead technology, it does not require centrifugation or advanced pipetting techniques, making the assay suitable for manual pipetting as well as automation. Researchers can, therefore, quickly detect changes in glycosylation, helping profile glycans that may effect changes in function, efficacy, and clearance of their biologics.
What does this mean for your lab, and how can you test the process yourself? To help you better understand the process, researchers documented the Fast Glycan Labeling and Analysis technology for N-glycosylation analysis in the following application note, “High-Resolution Separation and Identification in Minutes.”
Discover the winning combination for the lab using the PA 800 Plus Pharmaceutical Analysis System.Learn more >
For research use only. Not for use in diagnostic procedures.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network